TechFlash: Winners in Microsoft-LinkedIn deal; Fastest-growing tech companies

If you are having trouble viewing this email, click here

Here are the biggest winners in the $26.2 billion Microsoft-LinkedIn deal It's the Redmond company's largest-ever acquisition. LinkedIn shareholders will receive $196 per share, which equals billions of dollars for the company's top shareholders. 6 things you didn't know about Microsoft's megadeal to buy LinkedIn Microsoft is paying through the nose to buy LinkedIn, but that's not all. Seattle digital health company League scores $25M Series A round Seattle's digital health wellness platform League has landed a $25 million funding round, The company hopes the funds will help it further break into the $100 billion North American health insurance industry. Could Microsoft/LinkedIn deal scramble tech real estate plans? Both companies are major employers in Mountain View and Sunnyvale, and each has huge real estate expansion plans in the works. FAA fines Amazon $350,000 for shipping unmarked corrosive chemicals The Federal Aviation Administration has proposed a $350,000 for Amazon and said the retail giant has "a history of violating" regulations. These publicly traded tech companies are the fastest-growing in Washington Collectively, these 12 tech companies saw revenue increase more than 30 percent since 2013. Worker approved: PSBJ reveals Washington's Best Workplaces with 50-99 employees Puget Sound Business Journal's 2016 Washington's Best Workplaces with between 50 and 99 full-time employees all earned top scores from their employees. Why Taser is hiring in Seattle The Seattle division of Taser is looking to hire about 35 software engineers as it further develops its police-work computing platform and body cameras. Seattle biotech Alpine Immune Sciences lands $48M in Series A funding Seattle's Alpine Immune Sciences has pulled in $48 million in a Series A round, with the money to go toward the company's cancer and autoimmune disease therapies. Seattle biotech Acucela delays move to Japan, ends clinical trial The news comes as Acucela's development and manufacturing partner severed a 15-year agreement and halted clinical trials for its main drug therapy candidate Former dot com exec, venture capitalist: Why we won't have a repeat of the dot com bust Madrona Venture Group's Len Jordan tells us what helped companies fare through the dot com bust and what modern companies can learn from the collapse. National Tech News Zenefits to restructure, lay off 9 percent of workforce, shrink major office SpaceX launch coming up, ULA sets next date Local web design firm with Donald Trump presidential campaign contract offers 100 jobs as election nears Is digital health 'the digital snake oil of the 21st century'?

Connect with us   Companies in the News Microsoft LinkedIn Nokia Visio Corp. Skype Facebook BDC Puget Sound Business Journal League LinkedIn Corp. Google Amazon Notice of Proposed Civil Penalty United Parcel Service Tableau Zillow Group Microvision Data I/O KeyTronic F5 Networks BSquare Onvia Rightside Group Cray Best Workplaces Quantum Workplaces Taser Seattle Police Department Axon Frazier Healthcare Partners OrbiMed Advisors Alpine Immune Sciences Acucela Otsuka Pharmaceutical Madrona Venture Group RealNetworks

Text Version | Cancel Email Subscription You may change your email address, your preferences, or unsubscribe from this email at any time by visiting bizjournals.com: https://www.bizjournals.com/my_account/ If you need other assistance, please let us know or contact: bizjournals customer service, bizjournals.com 120 W. Morehead St. Charlotte, North Carolina 28202 © 2016 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this may not be reproduced, distributed, transmitted, cached or otherwise used, except with the written permission of bizjournals.com.